In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Cantargia AB, with a price target of SEK14.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sara Nik has given his Buy rating due to a combination of factors tied to Cantargia’s evolving clinical strategy and expanding pipeline. He views the decision to align nadunolimab development in pancreatic cancer with the emerging RAS inhibitor class as a value-enhancing pivot, aiming for a more differentiated and commercially relevant label as daraxonrasib advances toward first-line standard-of-care.
He also highlights the encouraging early signal from the Phase 1b MDS data, which has justified a dedicated hematologic malignancy program and sets up meaningful readouts by year-end 2026. In addition, accelerating platform news flow, including a second target for CAN14 and continued progress of the CANxx ADC program, adds strategic optionality beyond the core PDAC and MDS indications, supporting his unchanged $14 price target and Buy recommendation.